Merck bets $334m on Korea as Asia-Pacific biopharma hub

German science and technology company Merck has opened a $334 million bioprocessing plant in Daejeon, its largest life science investment in Asia-Pacific, as it seeks to bring production closer to regional drugmakers. The company said Thursday that the 44,500-square-meter facility in Dungok, Daejeon, will manufactur…

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.